877397-67-6

Basic information

• Product Name: Benzenemethanol, 2,6-dichloro-3-fluoro-a-methyl-, acetate
• CAS NO: 877397-67-6
• Molecular Formula: C10H9Cl2FO2
• Molecular Weight: 251.085
• Mol File: 877397-67-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 2,6-dichloro-3-fluoro-a-methyl-, acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2,6-dichloro-3-fluoro-a-methyl-, acetate(877397-67-6)
• EPA Substance Registry System: Benzenemethanol, 2,6-dichloro-3-fluoro-a-methyl-, acetate(877397-67-6)

Safety Data

• Hazardous Substances Data: 877397-67-6(Hazardous Substances Data)

Usage

Chemical compound

Benzenemethanol, 2,6-dichloro-3-fluoro-a-methyl-, acetate
Commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals
Derivative of benzenemethanol known for its antiseptic and disinfectant properties
Addition of 2,6-dichloro-3-fluoro and a-methyl groups enhances biological activity
Useful in development of new drugs and pesticides
Acetate group provides stability and solubility
Easier to handle and use in various applications
Potential uses in pharmaceutical and agricultural industries

Upstream product

• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 108-24-7 acetic anhydride 

Downstream Products

• 877397-65-4 (S)‐1‐(2,6-dichloro-3-fluorophenyl)ethanol 
• 877399-98-9 C₉H₉Cl₂FO₃S 
• 877397-68-7 (1S)-1-(2,6-dichloro-3-fluorophenyl)ethyl acetate 
• 330156-50-8 (R)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol 

Relevant articles and documents

CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER

The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.

CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER

The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.

Polymorphs of a C-Met/Hgfr Inhibitor

This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.